Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff

Kyle Blankenship

Astellas took a flier on women’s health when it bought out Ogeda and nonhormonal menopause candidate fezolinetant in early 2017 and then doubled down during …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff

Kyle Blankenship

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Astel­las scores a pair of tri­al wins for menopausal hot flash med, rais­ing the pitch of loom­ing Bay­er stand­off

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff